Product Information

GVOKE HYPOPEN 2-PK 1 MG/0.2 ML is a brand product labeled by Xeris Pharmaceuticals, Inc., priced at $1603.3466 per ML under NDC 72065012112. Its NADAC has been published 305 times since Oct 21, 2020.

FDA first approved this application on Sep 10, 2019.

GVOKE HYPOPEN 2-PK 1 MG/0.2 ML

glucagon injection, solution
$1603.3466per ML

Strength

1 mg/.2mL

NDC

72065012112

Classification

Brand

Dosage Form

INJECTION, SOLUTION

Route

SUBCUTANEOUS

Effective Date

8/19/2026

Active Ingredients

GLUCAGON

Approval Type

New Drug (NDA)

FDA Application

NDA212097

FDA Approved

9/10/2019

On Market Since

9/10/2019

Pharmacological Classes

Antihypoglycemic Agent
Decreased GI Motility
Decreased GI Smooth Muscle Tone
Decreased Glycolysis
Gastrointestinal Motility Inhibitor
Increased Gluconeogenesis
Increased Glycogenolysis

Price Statistics

The NADAC for GVOKE HYPOPEN 2-PK 1 MG/0.2 ML has been published 305 times since Oct 21, 2020, and over the history we have for it it has risen 18.7%. The table below summarizes its recorded NADAC range and movement.

Current price$1603.3466 per ML
All-time high$1603.3466 (Aug 19, 2026)
All-time low$1341.3857 (May 19, 2021)
52-week high$1603.3466
52-week low$1552.5642
Median price$1465.7826
Average price$1470.7348
Largest weekly change+3.0% (Feb 15, 2023)
Weeks tracked305
Tracking sinceOct 21, 2020

Price History

1W

+0.4%

1M

+0.4%

3M

+0.2%

6M

+0.2%

1Y

+3.3%

3Y

+9.4%

5Y

+19.5%

All

+18.7%

Generic Alternatives

The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 0% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Lowest-Cost Alternatives

Save up to 0%

1 alternative • Same active ingredient

Frequently asked questions

What is the NADAC price of GVOKE HYPOPEN 2-PK 1 MG/0.2 ML?

The current National Average Drug Acquisition Cost (NADAC) for GVOKE HYPOPEN 2-PK 1 MG/0.2 ML, manufactured by Xeris Pharmaceuticals, Inc., is $1603.3466 per ML (NDC 72065012112), effective Aug 19, 2026.

How has the price of GVOKE HYPOPEN 2-PK 1 MG/0.2 ML changed over time?

Over the history we have for it, the NADAC for GVOKE HYPOPEN 2-PK 1 MG/0.2 ML has risen 18.7%. It has been tracked across 305 weekly CMS publications since Oct 21, 2020.

What are the highest and lowest recorded NADAC prices for GVOKE HYPOPEN 2-PK 1 MG/0.2 ML?

Since Oct 21, 2020, the NADAC for GVOKE HYPOPEN 2-PK 1 MG/0.2 ML has ranged from a low of $1341.3857 (May 19, 2021) to a high of $1603.3466 (Aug 19, 2026), with a median of $1465.7826 per ML.

Are there cheaper alternatives to GVOKE HYPOPEN 2-PK 1 MG/0.2 ML?

Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, GVOKE PFS 1-PK 1 MG/0.2 ML SYR, is $1600.2289 per ML — about 0% below GVOKE HYPOPEN 2-PK 1 MG/0.2 ML.

Who manufactures GVOKE HYPOPEN 2-PK 1 MG/0.2 ML?

GVOKE HYPOPEN 2-PK 1 MG/0.2 ML (NDC 72065012112) is labeled by Xeris Pharmaceuticals, Inc., and CMS classifies it as a brand product.